PROTAC Degrader

PROTAC degraders recruit an E3 ubiquitin ligase to a target protein so that the proteasome degrades it. Each proteolysis-targeting chimera (PROTAC) links a target-binding ligand to an E3 ligase ligand through a chemical linker. The approach was first described in 2001, and later work showed that small-molecule PROTACs can act catalytically, removing several target copies per molecule. Examples include the bromodomain and extra-terminal (BET) degraders dBET1, MZ1 and ARV-771, and the estrogen receptor degrader ERD-308. Degraders of anti-apoptotic proteins, such as PROTAC Mcl1 degrader-1, are also listed.

Items 426-450 of 786

  • SMD-3236
    Cat. No.
    A40347

    SMD-3236

    SMD-3236 is a SMARCA2 PROTAC degrader that effectively induces the degradation of the SMARCA2 protein through proteasome- and ubiquitin-dependent mechanisms, achieving a DC50 of 0.5 nM and Dmax of 98%. It demonstrates an IC50 of 42.2 nM against human SMARCA2, providing significant growth inhibition in SMARCA4-deficient cancer cells. SMD-3236 has shown profound and sustained depletion of SMARCA2 in tumor tissues and suppresses tumor growth in relevant xenograft models. This reagent is valuable for research focusing on SMARCA4-deficient cancers, including melanoma, non-small cell lung cancer, and acute myeloid leukemia.

    Out of stock

    All 3 sizes
  • PROTAC BRD4 Degrader-10
    Cat. No.
    A40349

    PROTAC BRD4 Degrader-10

    PROTAC BRD4 Degrader-10 is a proteolysis-targeting chimera (PROTAC) designed to selectively degrade the BRD4 protein via recruitment of the von Hippel-Lindau (VHL) E3 ligase. This compound exhibits significant biological activity in degrading BRD4 in PC3 prostate cancer cells, demonstrating effective DC50 values of 1.3 nM when conjugated with STEAP1 antibodies and 18 nM with CLL1 antibodies. This reagent is valuable for studying the role of BRD4 in cancer biology and exploring targeted degradation strategies in therapeutic applications.

    1 mg
    $220.00
    5 mg
    $560.00
    All 6 sizes
  • PROTAC BRD9 Degrader-6
    Cat. No.
    A40365

    PROTAC BRD9 Degrader-6

    PROTAC BRD9 Degrader-6 is a highly effective degrader targeting BRD9, exhibiting an IC50 of 0.13 nM. This compound selectively induces proteolysis of BRD9, facilitating the study of diseases associated with the BAF complex. It is a valuable tool for researchers investigating the role of BRD9 in various biological contexts and its potential therapeutic applications.

    5 mg
    $420.00
    10 mg
    $680.00
    All 2 sizes
  • PROTAC SMARCA2/4-degrader-18
    Cat. No.
    A40372

    PROTAC SMARCA2/4-degrader-18

    PROTAC SMARCA2/4-degrader-18 is a dual-target PROTAC degrader that selectively degrades the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It exhibits potent degradation activity with DC50 values of less than 100 nM in A549 cells for SMARCA2 and MV411 cells for SMARCA4. This reagent is useful for investigating the functional roles of SMARCA2 and SMARCA4 in cellular processes and may provide new insights into therapeutic strategies targeting chromatin remodeling in cancer research.

    Out of stock

    All 3 sizes
  • PROTAC BRD4 Degrader-26
    Cat. No.
    A40373

    PROTAC BRD4 Degrader-26

    PROTAC BRD4 Degrader-26 is a photo-regulated PROTAC designed to selectively degrade BRD4 through a photocleavable linker. This compound achieves an impressive 80% degradation of BRD4 at a concentration of 1 μM, demonstrating significant potency. The degradation process can be controlled by UV light, allowing for precise temporal regulation of BRD4 levels. It is an essential tool for researchers investigating the role of BRD4 in various biological pathways and its potential as a therapeutic target.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-10
    Cat. No.
    A40375

    PROTAC SMARCA2/4-degrader-10

    PROTAC SMARCA2/4-degrader-10 targets the selective degradation of SMARCA2, exhibiting a DC50 value of less than 100 nM. This compound serves as a valuable tool in cancer research, facilitating studies on tumor biology and the therapeutic potential of targeting the BRG1/BRM-associated factor complex. The design incorporates a ligand linked to a VHL ligand, enhancing the efficacy of the degrader in cellular environments.

    Out of stock

    All 3 sizes
  • PROTAC BRD3 degrader-1
    Cat. No.
    A40380

    PROTAC BRD3 degrader-1

    PROTAC BRD3 Degrader-1 is a potent and selective proteolysis-targeting chimera (PROTAC) designed to degrade BRD3. Its mechanism involves the targeted degradation of BRD3, leading to the downregulation of H3K18ac while sparing BRD2 and BRD4. This compound demonstrates significant efficacy in reducing intraocular inflammation in the experimental autoimmune uveitis mouse model and inhibits pro-inflammatory responses in microglial cells, making it a valuable tool for uveitis research.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2 degrader-21
    Cat. No.
    A40386

    PROTAC SMARCA2 degrader-21

    PROTAC SMARCA2 degrader-21 is a targeted protein degradation compound that selectively degrades the SMARCA2 protein through the ubiquitin-proteasome system. It demonstrates potent biological activity with a DC50 value of 10-50 nM in A549 cells and exhibits even greater efficacy in MV411 cells, achieving a DC50 of less than 1 nM for SMARCA2 while showing limited degradation of SMARCA4 (DC50 >100 nM). This compound is useful for investigating the functional roles of SMARCA2 in cancer biology and therapeutic development.

    Out of stock

    All 3 sizes
  • BRD4 degrader-6
    Cat. No.
    A40391

    BRD4 degrader-6

    BRD4 degrader-6 is a dimeric PROTAC degrader targeting the BRD4 protein, demonstrating a DC50 of less than 0.1 μM. This compound facilitates the ubiquitination and subsequent degradation of BRD4, contributing to its anticancer properties. It serves as a valuable tool for studying BRD4-related pathways and potential therapeutic strategies in cancer research.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-6
    Cat. No.
    A40392

    PROTAC SMARCA2/4-degrader-6

    PROTAC SMARCA2/4-degrader-6, a targeted degrader of SMARCA2 and SMARCA4, employs a proteolysis-targeting chimeric approach to facilitate the degradation of these proteins. This compound demonstrates significant potential in cancer research by selectively lowering SMARCA2/4 levels, thereby disrupting oncogenic signaling pathways. Its unique structure includes a ligand for SMARCA2/4 and a VHL ligand to promote ubiquitination and subsequent proteasomal degradation, making it a valuable tool for elucidating the role of these proteins in tumor biology.

    Out of stock

    All 3 sizes
  • PROTAC BRD2/BRD4 degrader-1
    Cat. No.
    A40395

    PROTAC BRD2/BRD4 degrader-1

    PROTAC BRD2/BRD4 degrader-1 is an effective PROTAC targeting the BET proteins BRD4 and BRD2 with high selectivity. This compound facilitates the rapid and reversible degradation of BRD4 and BRD2, while sparing BRD3, making it a powerful tool for research into solid tumors. Its composition includes a BET inhibitor, a linker, and thalidomide, which targets cereblon (CRBN) and cullin 4A. This degrader demonstrates potential in cancer therapeutics with a minimal cytotoxic effect on cells.

    Out of stock

    All 3 sizes
  • BRD-SF2
    Cat. No.
    A40399

    BRD-SF2

    BRD-SF2 is a BRD4-targeted PROTAC degrader that facilitates the selective degradation of the BRD4 protein. With a DC50 of 17.2 μM, it utilizes a VHL ligand and a specific linker to induce proteasomal degradation. This compound is valuable for research applications in cancer biology and epigenetics, providing insights into the role of BRD4 in transcriptional regulation and cellular processes.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4 degrader-36
    Cat. No.
    A40404

    PROTAC SMARCA2/4 degrader-36

    PROTAC SMARCA2/4 degrader-36 is a selective dual degrader targeting SMARCA2 and SMARCA4, demonstrating DC50 values of 0.22 nM and 0.85 nM, respectively. This compound exhibits significant anti-cell proliferation activity, making it a valuable tool for research in cancer biology and epigenetic regulation. It employs a unique mechanism of action involving targeted protein degradation, which can provide insights into the functional roles of SMARCA2 and SMARCA4 in various cellular processes.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-17
    Cat. No.
    A40410

    PROTAC SMARCA2/4-degrader-17

    PROTAC SMARCA2/4-degrader-17 is an innovative PROTAC degrader designed to target the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF chromatin remodeling complex. This compound effectively induces the degradation of SMARCA2 in A549 cells and SMARCA4 in MV411 cells, exhibiting DC50 values of less than 100 nM for both targets. It presents a valuable tool for research studies focused on the modulation of chromatin dynamics and cancer biology.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4 degrader-39
    Cat. No.
    A40412

    PROTAC SMARCA2/4 degrader-39

    PROTAC SMARCA2/4 degrader-39 is a selective degrader that targets the SMARCA2 (BRM) and SMARCA4 (BRG1) proteins through the PROTAC mechanism. This compound exhibits significant efficacy in promoting the degradation of these chromatin remodeling proteins, which is crucial in various oncological contexts, particularly non-small cell lung cancer and colorectal cancer. Researchers may find this degrader valuable for studying the molecular mechanisms underlying tumor growth and developing innovative therapeutic strategies.

    Out of stock

    All 3 sizes
  • EN884
    Cat. No.
    A40415

    EN884

    EN884 is a selective degrader of BRD4, functioning through a SKP1- and proteasome-dependent mechanism. This compound facilitates targeted protein degradation and is applicable in synthetic proteolysis targeting chimeras (PROTACs) research. EN884 is valuable for investigating the role of BRD4 in various biological processes and disease contexts.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-29
    Cat. No.
    A40416

    PROTAC SMARCA2/4-degrader-29

    PROTAC SMARCA2/4-degrader-29 (Compound I-279) is a selective degrader aimed at the catalytic subunits of the SWI/SNF chromatin remodeling complexes, SMARCA2 and SMARCA4. This compound effectively induces the degradation of SMARCA2 in A549 cells and SMARCA4 in MV411 cells, achieving a degradation concentration (DC50) of less than 100 nM for both targets. It is designed for use in research focused on chromatin regulation, epigenetic modifications, and related therapeutic applications.

    Out of stock

    All 3 sizes
  • RAJQ14
    Cat. No.
    A40423

    RAJQ14

    RAJQ14 is a PROTAC degrader that selectively targets BRD4, facilitating its degradation through the ubiquitination-independent pathway. By binding to the 19S proteasome cap subunits RPN1, RPN10, RPN13, and USP14, RAJQ14 recruits BRD4 to the proteasome, promoting proteolytic degradation. This compound is an invaluable tool for cancer research, enabling studies of the mechanisms underlying BRD4 modulation and its role in tumor biology.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2 degrader-28
    Cat. No.
    A40425

    PROTAC SMARCA2 degrader-28

    PROTAC SMARCA2 degrader-28 is a selective PROTAC agent that targets SMARCA2, effectively inducing its degradation with a DC50 of 3 nM in HiBiT A549 cells. This compound utilizes a bifunctional mechanism, linking a ligand for SMARCA2 with an E3 ligase ligand, facilitating targeted protein degradation. It serves as a potent tool for research applications aimed at studying SMARCA2's role in cellular processes and its potential implications in cancer therapeutics.

    Out of stock

    All 3 sizes
  • EBET-1593
    Cat. No.
    A40431

    EBET-1593

    EBET-1593 is a selective BET PROTAC degrader that facilitates the ubiquitination and subsequent degradation of BET proteins. This compound serves as a lead payload for the synthesis of antibody-drug conjugates (ADCs), such as 84-EBET, which exhibits anti-tumor activity against pancreatic ductal adenocarcinoma. EBET-1593 is integral for research in targeted protein degradation and therapeutic strategies in oncology.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-19
    Cat. No.
    A40432

    PROTAC SMARCA2/4-degrader-19

    PROTAC SMARCA2/4-degrader-19 is designed to target the catalytic subunits of the SWI/SNF complex, specifically SMARCA2 and SMARCA4. This potent degrader effectively leads to the degradation of SMARCA2 in MV411 and A549 cells with a DC50 of less than 100 nM, as well as SMARCA4 in MV411 with a similar DC50. It serves as a valuable tool for researching the functional roles of these proteins in cancer biology and therapeutic development.

    Out of stock

    All 3 sizes
  • dBAZ2
    Cat. No.
    A40437

    dBAZ2

    dBAZ2 is a novel PROTAC degrader targeting BAZ2A and BAZ2B, demonstrating DC50 values of 180 nM and 250 nM, respectively. This compound facilitates the ubiquitination and subsequent proteasomal degradation of BAZ2A and BAZ2B, making it a valuable tool for studying their biological roles. dBAZ2 is suitable for research applications in cancer biology, epigenetics, and the exploration of targeted protein degradation mechanisms.

    5 mg
    $2,050.00
    10 mg
    $3,140.00
    All 3 sizes
  • AR/BET protein degrader-1
    Cat. No.
    A40439

    AR/BET protein degrader-1

    AR/BET protein degrader-1 is a PROTAC designed to selectively target and degrade both the Androgen Receptor (AR) and BET proteins. This compound exhibits potent biological activity in modulating protein levels, making it a valuable tool for cancer research. It facilitates novel therapeutic strategies aimed at overcoming resistance mechanisms, thereby enhancing the understanding of cancer biology and treatment options.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2 degrader-26
    Cat. No.
    A40444

    PROTAC SMARCA2 degrader-26

    PROTAC SMARCA2 degrader-26 is a specific degrader targeting the SMARCA2 protein. This compound exhibits potent activity, inducing a degradation of 94% for SMARCA2 and 57% for SMARCA4 in VCaP cells. Additionally, PROTAC SMARCA2 degrader-26 demonstrates significant antiproliferative effects, making it a valuable tool for research applications aimed at investigating the roles of SMARCA proteins in cancer and other diseases.

    Out of stock

    All 3 sizes
  • PROTAC SMARCA2/4-degrader-31
    Cat. No.
    A40447

    PROTAC SMARCA2/4-degrader-31

    PROTAC SMARCA2/4-degrader-31 is a targeted degradative agent designed to induce proteolytic degradation of the catalytic subunits SMARCA2 and SMARCA4 within the SWI/SNF chromatin remodeling complex. This compound demonstrates effective degradation of SMARCA2 in A549 cells with a DC50 of less than 100 nM and SMARCA4 in MV411 cells, also with a DC50 below 100 nM. It is a valuable tool for studying the functional roles of these proteins in cancer biology and epigenetic regulation.

    Out of stock

    All 3 sizes

Items 426-450 of 786

Added to your cart

View Cart Checkout

    Loading...